Opus Genetics (IRD) Reiterated at Market Outperform by Citizens on Key Learnings from BEST1 Cohort

October 16, 2026 4:52 AM

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $17.00 price target on Opus Genetics (NASDAQ: IRD).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found